NC-KBI-BIOPHARM/ARGONAUT
16.1.2024 13:58:26 CET | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and diagnostics industries, today announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions. The arrangement provides a seamless integration of drug substance and drug product manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish. The alliance reinforces both companies’ commitment to support customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116635207/en/
Biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.
“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development,” said J.D. Mowery, President and CEO of KBI Biopharma.
He continued, “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”
“We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations,” said Wayne Woodard, Founder and CEO of Argonaut. “Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products. With this collaboration, biopharmaceutical organizations can now seamlessly move from development to full-scale manufacturing, saving both time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
More information available at www.argonautms.com.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116635207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 16:33:00 CEST | Press release
New analysis shows destinations that assume risk will recover up to 1.5 times faster with global rehabilitation times dropping from 24 months to as little as 10 TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and mai
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 15:00:00 CEST | Press release
New admin-defined spend rules let businesses control how, where, and when every card is used, stopping the wrong spend before it happens instead of cleaning it up after. Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or le
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 14:30:00 CEST | Press release
New Travel Industry report reveals sophisticated fraud rings are exploiting trusted customer behaviors across flights, hotels, and travel platforms Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity i
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 13:54:00 CEST | Press release
Revenue rose 9% to $120 billion while net profit more than doubled to $17 billionCumulative domestic investments reached more than $199 billion since 2021PIF has contributed more than $342 billion to Saudi Arabia’s real non-oil GDP between 2021 and 2025Assets under management exceed $900 billion, up from around $530 in 2021 and $150 billion in 2015 PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom